Abstract:Background: Basal ganglia and thalamic arteriovenous malformations (AVMs) represent a special subset of malformations. Due to the involvement of vital brain structures and the specifically fine and delicate angioarchitecture of these lesions, it presents unique therapeutic challenges and technical difficulties that require thorough treatment planning, individualized treatment strategies, and advanced techniques for good clinical outcome. Method: In this study, we presented a series of ruptured basal ganglia and thalamic AVMs embolized via a transarterial, transvenous or combined approach. Herein, we summarized our treatment experience and clinical outcomes to further evaluate the effectiveness and safety of endovascular embolization for these AVMs as well as the indications, therapy strategies, and techniques of embolization procedures. Results: Twelve patients with basal ganglia and thalamus AVMs were included in the study. Their average age was 23.83 ± 16.51 years (range, 4–57 years) with a female predominance of 67% at presentation. The AVMs were located in the thalamus in 3 (25%) patients, in the basal ganglia in 3 (25%) patients, and in both sites of the brain in 6 (50%) patients. There were 5 AVMs located on the left side and 7 on the right. The mean nidus diameter was 3.32 ± 1.43 cm (range 1.3–6.1 cm). According to the Spetzler-Martin grading classification, 4 (33.3%) brain AVMs were Grade III, 7 (58.3%) were Grade IV, and 1 (8.3%) was Grade V. All of them presented with bleeding at admission: four of these patients presented with an intracerebral hemorrhage (ICH), 8 ICH in combination with intraventricular hemorrhage (IVH), and no patient with subarachnoid hemorrhage (SAH). Among these patients treated with endovascular embolization, 7 patients were treated by the transarterial approach, 4 patients transvenous approach, and 1 patient underwent the combined approach. A single embolization procedure was performed in 6 patients (50%) and the other 6 cases (50%) were treated in a staged manner with up to three procedures. Procedure-related complications occurred only in two patient (16.7%). Complete AVM obliteration was obtained in 7 patients (58.3%), and partial obliteration was in 4 patients (33.3%). Overall, good or excellent outcomes were obtained in 7 patients (58.3%), and poor functional outcome was observed in 5 patients (41.7%) at the last follow-up. All survived patients achieved anatomic stabilization and there was no postoperative bleeding or recurrence in the follow-up. Conclusion: The management of the basal ganglia and thalamic AVMs is a great challenge, which needs multimodal individualized treatment to improve the chances of radiographic cure and good outcomes. Endovascular therapy is safe and effective in the treatment of cerebral AVMs particularly for deep-seated AVMs such as the basal ganglia and thalamus. Our results demonstrate a high rate of anatomic obliteration with an acceptable rate of complications in the endovascular treatment of these vasculopathies via a transarterial approach or a transvenous approach.

Clinical Efficacy of Embolization in Treating Cerebral Arteriovenous Malformations Using a New Liquid Embolic Agent

Treatment of high grade cerebral anteriovenous malformations with Onyx embolic agent

[Clinical Analysis of Interventional Embolization for 9 Cases with Frontal Arteriovenous Malformation].

A Clinical Study of the Treatment of Cerebral Arteriovenous Malformations with Endovascular Embolization

Embolization of Arterial Gastrointestinal Hemorrhage with Fuaile Medical Adhesive

Computational Modeling and Simulation for Endovascular Embolization of Cerebral Arteriovenous Malformations with Liquid Embolic Agents

Microsurgical Excision Combined with Preoperational Endovascular Embolization in Treatment of Cerebral Arteriovenous Malformation

Endovascular embolization for basal ganglia and thalamic arteriovenous malformations

Technique of Fractionated Transcatheter Arterial Embolization for Treating Large Arteriovenous Malformation in Brain Functional Area.

[Clinical Experience of 70 Cases of Cerebral Arteriovenous Malformations Embolization with Onyx, a Novel Liquid Embolic Agent].

Clinical application in the embolization of cerebral arteriovenous malformation with onyx

Transcatheter arterial embolization with medical adhesive for nonvariceal gastrointestinal bleeding

Clinical Analysis Of 50 Cases Of Bavm Embolization With Onyx, A Novel Liquid Embolic Agent

Efficacy and safety of embolization for arteriovenous malformations of the basal ganglia and thalamus via the transarterial approach

Safety and efficacy of newer liquid embolic agents squid and PHIL in endovascular embolization of cerebral arteriovenous malformations and dural arteriovenous fistulas: A systematic review and meta-analysis

Transcatheter Embolization of Peripheral Renal Artery for Hemorrhagic Urological Emergencies Using FuAiLe Medical Glue

Efficacy of Liquid Embolic Agent Treatment in Hemorrhagic Peripheral Intracranial Aneurysms: A Single-Center Experience

Treatment of Cerebral Arteriovenous Malformations with a New Liquid Embolic Agent (Onyx18)

Embolization of Brain Arteriovenuous Malformations with NBCA

Percutaneous sclerotherapy of arteriovenous malformations of the maxillofacial soft tissues using fibrin glue combined with OK-432 and bleomycin following embolization in 13 consecutive patients

Clinical efficacy of transvenous curative embolization of intracranial arteriovenous malformations: a preliminary observation